Cyclopentolate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: January 16, 2026🚩 Report this page

Cyclopentolate

Anticholinergics

GB MHRA

Drug class: Anticholinergics
Availability: See label
Markets covered: 1
Products on record: 4

Overview

Cyclopentolate is an active pharmaceutical ingredient in the Anticholinergics group (S01FA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	January 16, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised December 12, 2025[1]

(i) Diagnostic purposes for fundoscopy and cycloplegic refraction. (ii) Dilating the pupil in inflammatory conditions of the iris and uveal tract.

How to take

Drug interactions

Known interactions involving Cyclopentolate. Select one for details. This list is informational and not a complete interaction checker.

Acetylcholine Bethanechol Carbamoylcholine Cevimeline Demecarium Donepezil Galantamine Isoflurophate Phenylephrine Physostigmine Pilocarpine Rivastigmine Tacrine

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL175090007 · revised December 12, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 12, 2025[1]

Frequencies are defined according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
System organ class Adverse reactions Frequency Psychiatric disorders abnormal behavioura, psychotic disordersa not known Nervous system disorders dizziness, convulsionsb, partial seizuresb not known Eye disorders eye pain, increased intraocular pressure, eye oedema1, eye irritation (stinging)1, ocular hyperaemia1, conjunctivitis1, photophobia2 not known Cardiac disorders bradycardia, tachycardia, palpitations, arrhythmia, cardiopulmonary failurea not known Vascular disorders flushing not known Gastrointestinal disorders dry mouth, vomiting, gastrointestinal hypomotility and constipation, abdominal distensionc, necrotising enterocolitisd not known Skin and subcutaneous disorders dry skin, skin rasha not known Renal and urinary disorders urinary urgency, urinary retention, dysuria not known General disorders and administration site conditions gait disturbance not known Notes General 1.
Following prolonged administration 2. Secondary to pupillary dilation Paediatric population a. Abnormal behaviour, psychotic disorders, cardiopulmonary failure and skin rashes have been reported in the paediatric population b. Convulsions and partial seizures have been reported in children, although the cases reported to date have been low in number or isolated.
c. Cases of abdominal distension have been reported in infants. d. Necrotising enterocolitis has been reported in preterm infants. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised December 12, 2025[1]

Because of the risk of precipitating angle-closure glaucoma in the elderly and others prone to raised intraocular pressure, an estimate of the depth of the anterior chamber should be made before use, particularly if therapy is likely to be intense or protracted.
Caution should be observed when drugs of this group are administered to patients with prostatic enlargement, coronary insufficiency or cardiac failure, or ataxia. Atropine-like effects have been reported as side-effects. Extreme caution is advised for use in children and individuals susceptible to belladonna alkaloids because of the increased risk of systemic toxicity.
Patients should be warned of the oral toxicity of this preparation, and advised to wash their hands after use. If accidentally swallowed, patients should be advised to seek medical attention. Use with caution in an inflamed eye as the hyperaemia greatly increases the rate of systemic absorption through the conjunctiva.
To reduce systemic absorption the lacrimal sac should be compressed at the medial canthus by digital pressure for at least two minutes after instillation of the drops. Paediatric population Use of mydriatic agents has been associated in preterm infants with feed intolerance, abdominal distention, increased gastric aspirate and rare cases of necrotising enterocolitis.
8).

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations